Tests N-acetylcysteine to prevent mouth sores from radiotherapy in head and neck cancer
Tests N-acetylcysteine against standard care for radiation mouth sores in head and neck cancer patients.
Plain-language title generated from the registry record
Registry title: Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06354712, who can take part
Where in Egypt
- Clinical Oncology and Nuclear Medicine of Mansoura University HospitalAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mansoura University
- Trial code
- NCT06354712
- Record updated
- 15 January 2025
- Original description
A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of N-acetylcysteine in the prevention of radiotherapy induced oral mucositis in Head and Neck cancer patients.Read full original descriptionShow less
Clinical Study Evaluating the Efficacy and Safety of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of N-acetylcysteine in the prevention of radiotherapy induced oral mucositis in Head and Neck cancer patients.
Inclusion: Adults >18 years diagnosed with squamous cell carcinoma of the head and neck scheduled to receive curative radiotherapy (Primary or postoperative) of at least 50 Gy with or without concurrent chemotherapy; Individuals with healthy mucosa; Adequate bone marrow function (Hemoglobin level ≥10 g/dL, platelet count ≥75 × 103/microliter, and absolute neutrophil count ≥1.5 × 103/microliter); Patients with ECOG performance ≤2.
Exclusion: Individuals receiving systemic analgesics; History of chemotherapy or radiotherapy; Signs of systemic infections; Liver disorders and renal failure with eGFR <30 ml/min/1.73m2 (by the MDRD equation); Pregnant and lactating women; Inability to follow instructions and complete the questionnaires.